Table 1 Patient and tumor characteristics
Characteristic | Surgery (N = 30) | Radiotherapy (N = 28) |
|---|---|---|
Age at diagnosis (years), median (range) | 62.5 (49–73) | 65 (47–73) |
Initial Gleason score | ||
6 | 2 (6.67%) | 6 (21.43%) |
3 + 4 | 8 (26.67%) | 3 (10.71%) |
4 + 3 | 11 (36.67%) | 12 (42.86%) |
8 | 4 (13.33%) | 1 (3.57%) |
9 | 5 (16.67%) | 6 (21.43%) |
Primary tumor classification | ||
p/cT1 | 0 (0%) | 5 (17.86%) |
p/cT2 | 11 (36.67%) | 8 (28.57%) |
p/cT3 | 19 (63.33%) | 15 (53.57%) |
Primary nodal status | ||
p/cN0 | 25 (83.33%) | 20 (71.43%) |
p/cN1 | 1 (3.33%) | 2 (7.14%) |
p/cNx | 4 (13.33%) | 6 (21.43%) |
Prior treatment | ||
RP | 7 (23.33%) | 7 (25.00%) |
RT | 8 (26.67%) | 11 (39.29%) |
RP + RT | 15 (50.00%) | 10 (35.71%) |
Adjuvant ADT prior to PET/CT | 16 (53.33%) | 10 (35.71%) |
D’Amico Score | ||
High risk | 26 (86.67%) | 17 (60.71%) |
Intermediate risk | 4 (13.33%) | 6 (21.43%) |
Low risk | 0 (0%) | 5 (17.86%) |
Time from diagnosis to PET/CT (years), median (range) | 6.5 (1–19) | 7.5 (1–17) |
Age at PET/CT (years), median (range) | 71.5 (62–79) | 73.5 (50–81) |
PSA at PET/CT (ng/ml), median (range) | 2.39 (0.44–17.8) | 2.42 (0.46–9.32) |
PSA-DT at PET/CT (mo), median (range) | 5.6 (1.2–156) | 8.4 (0.7–55) |
Number of lesions at PET/CT | ||
1 | 16 (53.33%) | 24 (85.71%) |
2 | 8 (26.67%) | 3 (10.71%) |
3–5 | 6 (20.00%) | 1 (3.57%) |
Site of lesion | Na = 54 | Nb = 33 |
Local recurrence | 7 (12.96%) | 9 (27.27%) |
Regional lymph node | 42 (77.78%) | 12 (36.36%) |
Distant lymph node | 3 (5.56%) | 3 (9.09%) |
Bone | 2 (3.70%) | 9 (27.27%) |
SULmax sum, median (range) | 16.41 (2.51–68.95) | 6.17 (2.60–74.15) |
MTV sum, median (range) | 3.38 (1.11–13.89) | 2.26 (1.00–29.21) |
TLG sum, median (range) | 14.16 (1.23–236.12) | 7.19 (0.91–281.23) |